Prostate health index (PHI) and, more recently, Proclarix have been proposed as serum biomarkers for prostate cancer (PCa). In this study, we aimed to evaluate Proclarix and PHI for predicting clinically significant prostate cancer (csPCa).
New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index / Terracciano, Daniela; LA CIVITA, Evelina; Athanasiou, Alcibiade; Liotti, Antonietta; Fiorenza, Mariano; Cennamo, Michele; Crocetto, Felice; Tennstedt, Pierre; Schiess, Ralph; Haese, Alexander; Ferro, Matteo; Steuber, Thomas. - In: THE PROSTATE. - ISSN 0270-4137. - (2022). [10.1002/pros.24422]
New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index
Daniela Terracciano;Evelina La Civita;Antonietta Liotti;Michele Cennamo;Felice Crocetto;Matteo Ferro;
2022
Abstract
Prostate health index (PHI) and, more recently, Proclarix have been proposed as serum biomarkers for prostate cancer (PCa). In this study, we aimed to evaluate Proclarix and PHI for predicting clinically significant prostate cancer (csPCa).| File | Dimensione | Formato | |
|---|---|---|---|
|
authorservices.wiley.com 16_08_2022, 14_57_22.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Dominio pubblico
Dimensione
1.12 MB
Formato
Adobe PDF
|
1.12 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
